patent.fyi
Applications  /  US 2026/0356816
United States Patent Application Publication

US 2026/0356816 A1

Published
Nov 12, 2026
Filed
Jun 25, 2026
Earliest date on the face
Jun 4, 2018
Classification
C07D 401/14
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Sulfur at the carbonyl site

What ifWhat if Y is sulfur and the ring bears an exocyclic C=S bond?
Claim language“Y is O”

Thionation of the ring carbonyl gives a pyridazinethione. The C=S group retains a trigonal ring carbon and presents a larger, more polarizable sulfur atom at the edge of the ring.

1.2Carbon at the X1 site

What ifWhat if X1 is a ring carbon bearing one hydrogen?
Claim language“X1 is N”

The X1 carbon forms bonds to both neighboring ring atoms and contributes a p orbital to the conjugated core. Its C–H bond projects from the ring edge, and the ring carbonyl remains a hydrogen-bond acceptor.

1.6Three methylene spacer units

What ifWhat if n is 3 in the methylene linker?
Claim language“n is 1 or 2”

Three consecutive methylene groups connect the core to R5 through single bonds. The extra methylene increases the maximum reach of the terminal ring and adds a rotatable carbon–carbon bond.

1.7Fluorine at both ring sites

What ifWhat if R3 and R4 are both fluorine?
Claim language“R3 and R4 are hydrogen”

X2 and X3 each form a C–F bond and retain their positions in the conjugated ring. The two C–F bond dipoles change the electrostatic surface along that edge of the core.

1.8Thiazole as the terminal ring

What ifWhat if R5 is thiazol-2-yl?
Claim language“R5 is pyridyl, pyrazinyl, pyrimidinyl, triazinyl, or pyridazinyl”

The linker bonds to carbon 2 of a five-membered aromatic ring containing sulfur and nitrogen. The ring nitrogen supplies a hydrogen-bond acceptor, and the five-membered ring changes the angle between that acceptor and the linker.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Check sample recovery in water analysis

An isolated pyridazinone with a pyridyl A group and a methylene-linked pyrazinyl R5 serves as a recovery tracer in a water-analysis laboratory. The laboratory adds the tracer to one water aliquot before solid-phase extraction and to a matched aliquot after extraction. Liquid chromatography measures both aliquots at the same final volume, and the ratio of their peak areas gives the fraction recovered during sample preparation.

Component substitution

Substitute an oxadiazole terminal ring

A 5-methyl-1,2,4-oxadiazol-3-yl group replaces R5 at the end of a methylene linker. Ring carbon 3 bonds to the methylene carbon, and ring carbon 5 bears the methyl group. The pyridazinone carbonyl, the pyridyl A group, and the hydrogen atoms at R3 and R4 remain in place.

Insert oxygen into the R2 linker

A methylene–oxygen–methylene linker replaces the hydrocarbon segment between the pyridazinone scaffold and a pyridin-3-yl R5 group. The scaffold bonds to the first methylene, and the second methylene bonds to carbon 3 of the pyridine ring. The ether oxygen adds a hydrogen-bond acceptor between the two methylene groups.

Parameter or scale variation

Extend the methylene linker length

A two-member series uses three and four methylene units between the pyridazinone scaffold and a pyridin-3-yl terminal ring. Each member uses the same unsubstituted pyridyl A group and retains hydrogen at R3 and R4. The side chain bonds to the scaffold through its first carbon and to carbon 3 of the terminal pyridine through its last carbon.

Combination with existing systems

Couple chromatographic separation to fraction collection

A preparative reversed-phase liquid chromatograph separates pyridazinone derivatives on a column packed with octadecyl-bonded silica. An aqueous-to-acetonitrile gradient carries the separated components through an ultraviolet detector, and a split stream enters a mass spectrometer. The fraction collector opens a collection window when the target mass signal crosses a set threshold and applies a delay that accounts for transit from the stream split to the collection valve.

Automated or data-driven variant

Enumerate heteroaryl attachment sites automatically

Software stores the pyridazinone scaffold as a molecular graph with attachment points for A and the R2 linker. It joins pyridyl and pyrimidinyl fragments to those points at each ring carbon bearing a replaceable hydrogen and generates regioisomers with one fluoro or methoxy substituent at a remaining ring carbon. It checks atom valences, removes duplicate structures using canonical graph identifiers, and exports a structure record and calculated molecular mass for each retained compound.

Specific version of a part

Two methylenes to R5

R2 is —CH2CH2–R5, with the first methylene bonded to the core and the second bonded to R5. Rotation about the bond between the methylenes changes the orientation of R5 relative to the core.

Unsubstituted pyrazinyl terminal ring

R5 is an unsubstituted pyrazin-2-yl group attached through carbon 2. Its two aromatic nitrogen atoms occupy opposite positions in the six-membered ring.

Fluorinated pyridyl A ring

A is 5-fluoropyridin-3-yl and connects to the rest of the molecule through carbon 3. A single fluorine occupies carbon 5, and the pyridine nitrogen provides a hydrogen-bond acceptor.

Trifluoromethyl in an alkoxy group

Ra is trifluoromethyl, a one-carbon haloalkyl group with three fluorines on the same carbon. In ORa, oxygen connects the aromatic ring to that carbon to form an —OCF3 substituent.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 7,122,544 B2
Published
Oct 17, 2006
Filed
Dec 4, 2001
Class
A61K 31/506
Document BUS 2014/0073801 A1
Published
Mar 13, 2014
Filed
Aug 29, 2013
Class
C07D 207/12
Claim 1
Document A
Document B
1.1Y is O
Oxidation of the thioether with organic and inorganic oxidizing agents, such as m-chloroperbenzoic acid or oxone, yields the sulfones which, upon condensation with p-aminocarbonylanilines, give rise to the formation of the desired anilinopyrimidine derivatives.
A · US 7,122,544 B2 · ¶ 67
1.2X1 is N
1.3X2 is CR3
1.4X3 is CR4
1.5R2 is —(CH2)nR5, —(CH(CH3))nR5, or —(CH2CH(NH2))nR5
1.6n is 1 or 2
1.7R3 and R4 are hydrogen
1.8R5 is pyridyl, pyrazinyl, pyrimidinyl, triazinyl, or pyridazinyl, optionally substituted by 1 or 2 independently selected RB groups
R8, R9, R10, and R11 are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, phenyl or naphthyl, substituted phenyl or naphthyl, aralkyl, substituted arylalkyl, substituted or unsubstituted pyridyl, furyl, beazofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, beazothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, tria
A · US 7,122,544 B2 · claim 1
The aryl groups of the invention may optionally be substituted by one or more halogen atoms. Examples of aromatic moieties are benzene, naphthalene, imidazole and pyridine.
B · US 2014/0073801 A1 · ¶ 90
1.9A is pyridyl, pyrazinyl, pyrimidinyl, triazinyl, or pyridazinyl, optionally substituted by 1 or 2 independently selected RA groups
A compound having the structure: or a pharmaceutically acceptable salt thereof, wherein: R1 is phenyl, naphthyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, or quinazolinyl, optionally substituted with one to four substituents independently selected from R7;
A · US 7,122,544 B2 · claim 1
1.10each RA and RB is independently selected from the group consisting of halo, C1-6alkyl, and ORa
R4 represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl and lower alkoxy;
A · US 7,122,544 B2 · claim 1
C1-15 alkyl or alkenyl optionally substituted with one or more OH, OR10, ═O, NH2, N3, SH, SOxR10, halo, CN, NO2, NR10R11, (NR10)NR10R11, NH(NR10)NR10R11, CO2R10, OC(O)R10, P(O)(OR10)2, aryl or carbocyclyl groups; carbocyclyl or aryl, either of which is optionally substituted with one or more OH, OR10, ═O, NH2, N3, SH, SO9R10, halo, CN, NO2, NR10R11, (NR10)NR10R11, NH(NR10)NR10R11, CO2R10, OC(O)R10, P(O)(OR10)2, C1-9 alkyl optionally substituted with one or more OH, OR10, ═O,
B · US 2014/0073801 A1 · ¶
1.11each Ra is independently selected from the group consisting of hydrogen, C1-6alkyl, and C1-4haloalkyl.
O-phosphate or a group which together with the endocyclic carbon forms a spiro ring R10 represents H; C1-6 alkyl, optionally substituted with one or more OH, halo; aryl or C1-4 alkyl optionally substituted with aryl; and R11 represents H;
B · US 2014/0073801 A1 · ¶

An empty cell means only that no passage was reproduced there.

Statements in these documents
This invention is generally directed to anilinopyrimidine derivatives that have utility as IκB kinase (IKK) inhibitors, and particularly as IKK-2 inhibitors, as well to related compositions and methods.
A · US 7,122,544 B2 · ¶ 2
IKK enzymes show relatively low sequence homologies with other kinases, and early profiles with known kinase inhibitors have not identified compounds with striking potency.
A · US 7,122,544 B2 · ¶ 4
The invention relates to compounds, in particular iminosugars, methods of manufacture of the compounds, and the use of these compounds in the treatment of diseases or disorders responsive to inhibition of O-GlcNAcase.
B · US 2014/0073801 A1 · ¶ 1
In particular, the invention relates to the use of an iminosugar compound a prodrug thereof and a pharmaceutical composition comprising the compound or the prodrug for selective inhibition of O-GlcNAcase enzymes including human OGA.
B · US 2014/0073801 A1 · ¶ 1
Cite aspatent.fyi, US 2026/0356816 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356816/, SHA-256 c9216a64532375781407643055e9b86c4e35a5c8652f67286d1bb428cfd862f5
First published
Permanent addresshttps://patent.fyi/US20260356816/
Content fingerprint (SHA-256)c9216a64532375781407643055e9b86c4e35a5c8652f67286d1bb428cfd862f5
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi